Indication is for add-on maintenance treatment of children aged 6 to 11 years with severe eosinophilic asthma<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, April 16, 2024 (HealthDay News) — The U.S. Food and Drug Administration has approved an additional indication for Fasenra (benralizumab) as an add-on maintenance treatment for patients aged 6 to 11 years with severe asthma and an eosinophilic phenotype.<\/p>\n
This indication was supported by evidence from the phase 3 TATE trial, as well as data from additional well-controlled trials in adult and adolescent populations. Results among children aged 6 to 11 years old show that Fasenra met the primary end points, demonstrating pharmacokinetics and pharmacodynamics with severe eosinophilic asthma. The safety and tolerability results were also consistent with the known profile.<\/p>\n
The recommended dose for Fasenra is 30 mg for patients ages 6 years and older who weigh \u00e2\u0089\u00a535 kg, while a new 10-mg dose will be available for patients aged 6 to 11 years who weigh <35 kg. Fasenra is administered by subcutaneous injection every four weeks for the first three doses and then every eight weeks.<\/p>\n
“We welcome additional treatment options for children living with severe asthma, a condition that remains complicated to manage, further helping to address the unmet need in this patient population and reducing the burden of disease for the broader asthma community,” Lynda Mitchell, of the Allergy & Asthma Network, said in a statement.<\/p>\n
Approval of this indication for Fasenra was granted to AstraZeneca.<\/p>\n